New York State Common Retirement Fund grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 219,793 shares of the company's stock after buying an additional 29,000 shares during the period. New York State Common Retirement Fund's holdings in Roivant Sciences were worth $2,600,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in ROIV. FMR LLC raised its position in shares of Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the period. State Street Corp lifted its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares during the period. Geode Capital Management LLC grew its stake in shares of Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. TOMS Capital Investment Management LP bought a new position in shares of Roivant Sciences in the third quarter valued at $46,333,000. Finally, Loomis Sayles & Co. L P lifted its position in shares of Roivant Sciences by 13.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after acquiring an additional 458,601 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $18.08.
View Our Latest Research Report on ROIV
Insider Activity at Roivant Sciences
In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00. Following the transaction, the chief operating officer now owns 595,580 shares of the company's stock, valued at $6,843,214.20. This trade represents a 14.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of Roivant Sciences stock in a transaction dated Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 2,388,170 shares of company stock valued at $27,612,299. Insiders own 7.90% of the company's stock.
Roivant Sciences Stock Up 3.7 %
Shares of ROIV traded up $0.38 during midday trading on Wednesday, reaching $10.70. 6,668,477 shares of the stock were exchanged, compared to its average volume of 4,446,216. The company has a market cap of $7.63 billion, a price-to-earnings ratio of -71.33 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $9.76 and a 12-month high of $13.06. The firm has a 50 day simple moving average of $11.01 and a 200-day simple moving average of $11.57.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
